TY - JOUR T1 - Functional proteomic profiling links deficient DNA clearance to mortality in patients with severe COVID-19 pneumonia JF - medRxiv DO - 10.1101/2022.01.25.22269616 SP - 2022.01.25.22269616 AU - Iker Valle Aramburu AU - Dennis Hoving AU - Spyros I. Vernardis AU - Martha Tin AU - Vadim Demichev AU - Elisa Theresa Helbig AU - Lena Lippert AU - Klaus Stahl AU - Marianna Ioannou AU - Mia I. Temkin AU - Matthew White AU - Helena Radbruch AU - Jana Ihlow AU - David Horst AU - Scott T. Chiesa AU - John E. Deanfield AU - Sascha David AU - Christian Bode AU - Florian Kurth AU - Markus Ralser AU - Venizelos Papayannopoulos Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/01/25/2022.01.25.22269616.abstract N2 - Hyperinflammation, coagulopathy and immune dysfunction are prominent in patients with severe infections. Extracellular chromatin clearance by plasma DNases suppresses such pathologies in mice but whether severe infection interferes with these pathways is unclear. Here, we show that patients with severe SARS-CoV-2 infection or microbial sepsis exhibit low extracellular DNA clearance capacity associated with the release of the DNase inhibitor actin. Unlike naked DNA degradation (DNase), neutrophil extracellular trap degradation (NETase) was insensitive to G-actin, indicating distinct underlying mechanisms. Activity-based proteomic profiling of severely ill SARS-CoV-2 patient plasma revealed that patients with high NETase and DNase activities exhibited 18-fold higher survival compared to patients with low activity proteomic profiles. Remarkably, low DNA clearance capacity was also prominent in healthy individuals with chronic inflammation, suggesting that pre-existing inflammatory conditions may increase the risk for mortality upon infection. Hence, functional proteomic profiling illustrates that non-redundant DNA clearance activities protect critically ill patients from mortality, uncovering protein combinations that can accurately predict mortality in critically ill patients.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Francis Crick Institute which receives its core funding from the UK Medical Research Council (FC0010129, FC001134), Cancer Research UK (FC0010129, FC001134) and the Wellcome Trust (FC0010129, FC001134). I.V.A was funded by an EMBO LTF (ALTF 113-2019). S.T.C. was funded by BHF project grant PG/18/45/33814.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:For the in vitro neutrophil experiments, peripheral blood was isolated from consenting healthy adult volunteers, according to approved protocols of the ethics board of the Francis Crick Institute and the Human Tissue act. Sepsis patient samples were provided by the Hannover Medical School approved the ethics committee under the study protocol (No. 2786-2015). Written informed consent was obtained from participants or authorized representatives. The study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. No funding specific to this project was received. Sampling was performed as part of the Pa-COVID-19 study, a prospective observational cohort study assessing pathophysiology and clinical characteristics of patients with COVID-19 at Charité Universitätsmedizin Berlin. All patients with SARS-CoV-2 infection proven by positive PCR from respiratory specimens and willing to provide written informed consent are eligible for inclusion. Exclusion criteria are refusal to participate in the clinical study by patient or legal representative or clinical conditions that do not allow for blood sampling. The study assesses epidemiological and demographic parameters, medical history, clinical course, morbidity and quality of life during hospital stay of COVID-19 patients. Moreover, serial high-quality bio-sampling consisting of various sample types with deep molecular, immunological and virological phenotyping is performed. Treatment and medical interventions follow standard of care as recommended by current international and German guidelines for COVID-19. Severity of illness in the present study follows the WHO ordinal outcome scale. The Pa-COVID-19 study is carried out according to the Declaration of Helsinki and the principles of Good Clinical Practice (ICH 1996) where applicable and was approved by the ethics committee of Charité Universitätsmedizin Berlin (EA2/066/20). Plasmas of healthy donors with and without inflammation signatures were selected from participants in the Avon Longitudinal Study of Parents and Children (ALSPAC). All ethical approvals conformed to the Declaration of Helsinki and all biological samples used in the study were collected in accordance with the Human Tissue Act (2004).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -